Qiu Yi, Huang Shiyuan, Peng Li, Yang Li, Zhang Guosong, Liu Tao, Yan Fang, Peng Xi
Sichuan Industrial Institute of Antibiotics School of Pharmacy Chengdu University Chengdu China.
Department of Endocrinology and Metabolism Shanghai Pudong Gongli Hospital Pudong New Area Shanghai China.
MedComm (2020). 2025 Jun 6;6(6):e70213. doi: 10.1002/mco2.70213. eCollection 2025 Jun.
The blood-brain barrier (BBB) is a highly selective and protective barrier that restricts the entry of most therapeutic agents into the central nervous system (CNS), posing a significant challenge for the treatment of CNS diseases. The nose-to-brain drug delivery (NBDD) route has emerged as a promising strategy to bypass the BBB, offering direct, noninvasive, and efficient transport of drugs to the brain. This review begins with a concise overview of the BBB structure and its biofunctions, followed by an in-depth discussion of the mechanisms underlying the nose-to-brain pathway, including the olfactory and trigeminal nerve routes, and respiratory pathway. We further highlight the therapeutic research development of neurodegenerative diseases, acute neurological diseases, brain tumor, and psychiatric disorders when using NBDD drugs encompassing small-molecule drugs, proteins, peptides, nucleic acids, siRNA, and herbal compounds, in which we also introduce innovative delivery systems, including nanocarriers and novel platforms such as exosomes, which enhance drug stability, targeting efficiency, and bioavailability. In addition, we provide a comprehensive overview of recent clinical advancements in therapeutics delivered via the intranasal route for CNS diseases. Finally, we discuss the challenges and future directions of NBDD, emphasizing its potential to transform the treatment landscape for CNS disorders.
血脑屏障(BBB)是一种高度选择性的保护屏障,它限制了大多数治疗药物进入中枢神经系统(CNS),这给中枢神经系统疾病的治疗带来了重大挑战。鼻-脑给药(NBDD)途径已成为一种有前景的绕过血脑屏障的策略,它能将药物直接、无创且高效地输送到大脑。本文首先简要概述血脑屏障的结构及其生物功能,接着深入讨论鼻-脑途径的潜在机制,包括嗅觉和三叉神经途径以及呼吸途径。我们进一步强调了在使用包括小分子药物、蛋白质、肽、核酸、siRNA和草药化合物在内的NBDD药物治疗神经退行性疾病、急性神经系统疾病、脑肿瘤和精神疾病方面的研究进展,其中还介绍了创新的给药系统,包括纳米载体和外泌体等新型平台,这些系统可提高药物稳定性、靶向效率和生物利用度。此外,我们全面概述了通过鼻内途径递送治疗中枢神经系统疾病药物的近期临床进展。最后,我们讨论了NBDD面临的挑战和未来方向,强调了其改变中枢神经系统疾病治疗格局的潜力。